Cell line · CVCL_0367
Papers70
65 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 70
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The role of cardiomyocytic FOXP3 and extracellular vesicle-mediated delivery of FOXP3 into cardiomyocytes for treating pathological cardiac hypertrophy. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reassessment of the roles of coronin proteins as actin effectors and in signaling. | PLoS Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Specialized cortical ER architecture modulates Ca2+ signaling dynamics. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD3, CD28, TCRαβ expression and IL-2 production in a spontaneous glycosylphosphatidylinositol-deficient Jurkat T cell line. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intrathecal Allogeneic B7-H3-Targeted CAR γδ T Cells for Leptomeningeal Metastasis from Solid Tumors: Safety, Efficacy, and Immunologic Dynamics in a Phase I Trial. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mechanoadaptation via Myosin Cytoplasmic Redistribution Protects Circulating Tumor Cells From Shear-induced Death During Hematogenous Dissemination. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR-T Cell Engineering. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Human LFA-1 governs T cell immune surveillance of the skin. | Sci Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HIV-1 establishes immediate latency in T cells expressing the viral Nef protein. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lithium attenuates HIV-1 latency reversal in an autophagy-independent way. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The non-catalytic DNA polymerase ε subunit is an NPF motif recognition protein. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A novel strategy to target metabolic dependencies in acute myeloid leukemia. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Hyperactive PLCG1 induces cell-autonomous and bystander T cell activation and drug resistance. | EMBO Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Alzheimer's Disease-Associated Amyloid-β Precursor Protein Prevents Aging Stress-Induced Mitophagy and Fumarate Depletion to Improve Antitumor Immunity. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Responses to membrane potential-modulating ionic solutions measured by magnetic resonance imaging of cultured cells and in vivo rat cortex. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0367/papers